Capricor Therapeutics Inc
NASDAQ:CAPR
Capricor Therapeutics Inc
NASDAQ:CAPR
Price:
27.77
USD
-3.91%
Market Closed
Market Cap:
$1.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
US |
|
N
|
Nayax Ltd
TASE:NYAX
|
IL |
|
M
|
MultiChoice Group Ltd
JSE:MCG
|
ZA |
|
Bank Capital Indonesia Tbk PT
IDX:BACA
|
ID |
|
Asuransi Jasa Tania Tbk PT
IDX:ASJT
|
ID |
|
I
|
InnoTek Ltd
SGX:M14
|
SG |
|
E
|
Expleo Solutions Ltd
NSE:EXPLEOSOL
|
IN |
|
W
|
Weng Fine Art AG
XETRA:WFA
|
DE |
|
3P Learning Ltd
ASX:3PL
|
AU |
|
Select Sands Corp
XTSX:SNS
|
CA |
|
A
|
Amata VN PCL
SET:AMATAV
|
TH |
|
P
|
Port of Tauranga Ltd
NZX:POT
|
NZ |
|
Stallion Uranium Corp
OTC:STLNF
|
CA |
|
P
|
Pioneer Global Group Ltd
HKEX:224
|
HK |
|
Auxly Cannabis Group Inc
TSX:XLY
|
CA |
|
D
|
Duong Hieu Trading and Mining JSC
VN:DHM
|
VN |
|
UDR Inc
NYSE:UDR
|
US |
Multiples-Based Value
The Multiples-Based Value of one
CAPR
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 27.77 USD,
Capricor Therapeutics Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CAPR Multiples-Based Value
LOCKED
Multiples Across Competitors
CAPR Competitors Multiples
Capricor Therapeutics Inc Competitors
Capricor Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
1.3B USD | 0 | -12.1 | -9 | -8.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
376.8B USD | 6.2 | 90 | 14.9 | 20.7 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.2B USD | 109.7 | -1 712.3 | 15 906.4 | -1 796.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.1B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169.2B USD | 5.8 | 19.9 | 12.4 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.6B USD | 9.4 | 28.5 | 21.4 | 22.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.9B AUD | 3.1 | 34.8 | 11.5 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
